Search by Drug Name or NDC

NDC 71335-0639-02 LAMIVUDINE and ZIDOVUDINE 150; 300 mg/1; mg/1 Details

LAMIVUDINE and ZIDOVUDINE 150; 300 mg/1; mg/1

LAMIVUDINE and ZIDOVUDINE is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bryant Ranch Prepack. The primary component is LAMIVUDINE; ZIDOVUDINE.

MedlinePlus Drug Summary

The combination of lamivudine and zidovudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Lamivudine and zidovudine are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). They work by decreasing the amount of HIV in the blood. Although the combination of lamivudine and zidovudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.

Related Packages: 71335-0639-02
Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lamivudine and Zidovudine

Product Information

NDC	71335-0639
Product ID	71335-0639_aa348cf2-2e1b-486f-9bec-5ccf67879175
Associated GPIs
GCN Sequence Number	n/a
GCN Sequence Number Description	n/a
HIC3	n/a
HIC3 Description	n/a
GCN	n/a
HICL Sequence Number	n/a
HICL Sequence Number Description	n/a
Brand/Generic	n/a
Proprietary Name	LAMIVUDINE and ZIDOVUDINE
Proprietary Name Suffix	n/a
Non-Proprietary Name	LAMIVUDINE and ZIDOVUDINE
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	TABLET, FILM COATED
Route	ORAL
Active Ingredient Strength	150; 300
Active Ingredient Units	mg/1; mg/1
Substance Name	LAMIVUDINE; ZIDOVUDINE
Labeler Name	Bryant Ranch Prepack
Pharmaceutical Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosi
DEA Schedule	n/a
Marketing Category	ANDA
Application Number	ANDA079124
Listing Certified Through	2024-12-31

Package

NDC 71335-0639-02 (71335063902)

Pricing Information	N/A
NDC Package Code	71335-0639-2
Billing NDC	71335063902
Package	60 TABLET, FILM COATED in 1 BOTTLE (71335-0639-2)
Marketing Start Date	2021-12-27
NDC Exclude Flag	N